Effect of different modes of administration of Remimazolam on the induction period of anesthesia in gynecological day surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070710

Enrollment

Unknown

Registered

2023-04-20

Start date

2023-04-21

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group B:Remimazolam 0.3mg/kg

Group C:Remimazolam 0.25mg/kg

Group A:Remimazolam 6mg/kg/h

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Gynecological patients who are scheduled to undergo hysteroscopy under total intravenous anesthesia; 2. ASA I-II grade; 3. BMI 18-28; 4. Aged 18-65 years.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to any ingredients such as Remimazolam and micuramide; 2. Patients with schizophrenia and severe depression; 3. Acute upper respiratory tract infection; 4. Poorly controlled severe hypertension; 5. History of alcohol abuse and long-term use of sedative analgesics and history of allergies; 6. Markov airway classification grade IV, those who require awake tracheal intubation as determined by the investigator; 7. Breastfeeding period female; 8. Other circumstances determined by the researcher to be unsuitable for selection; 9. The operation time is more than 1 hour; 10. Patients who have been hospitalized for more than 24 hours; 11. Patients who have been dropped out after surgery.

Design outcomes

Primary

Measure	Time frame
Induction success rate of Remimazolam;	—

Secondary

Measure	Time frame
Time the patient fell asleep;Changes in hemodynamics at different times;Incidence of adverse reactions;time of waking;	—

Countries

China

Contacts

Public ContactJi Fanceng

Weifang People's Hospital

jifanceng@163.com+86 13563698838

Outcome results